Metabolic syndrome is associated with an increased risk of cardiovascular disease, type 2 diabetes, and breast cancer recurrence in survivors of breast cancer. This randomized controlled trial assessed the effects of a 16-week combined aerobic and resistance exercise intervention on metabolic syndrome, sarcopenic obesity, and serum biomarkers among ethnically diverse, sedentary, overweight, or obese survivors of breast cancer.
INTRODUCTION
Metabolic syndrome includes visceral adiposity, hyperglycemia, low-serum, high-density lipoprotein cholesterol, hypertriglyceridemia, and hypertension, 1 and is associated with a 17% increase in the risk of breast cancer, 2-4 a three-fold increase in breast cancer recurrence, and an approximate twofold increase in breast cancer-specific mortality. 5, 6 Metabolic syndrome is exacerbated by obesity, sedentary lifestyle, and the receipt of chemotherapy in patients with breast cancer. Interventions to improve metabolic syndrome among survivors of breast cancer are needed to reduce the risk of comorbidities and improve breast cancer outcomes.
Exercise improves individual components of metabolic syndrome in survivors of breast cancer [7] [8] [9] ; however, consensus is lacking that it improves metabolic syndrome as a collective entity, particularly in high-risk survivors of breast cancerracial and/or ethnic minorities with obesity. 5 The purpose of this trial was to examine the effects of a 16-week supervised aerobic and resistance exercise intervention on comprehensive metabolic syndrome parameters among ethnically diverse, sedentary, overweight, or obese survivors of breast cancer. Secondary outcomes included sarcopenic obesity and circulating biomarkers. We also examined outcomes in the exercise group 3-months after the completion of the intervention.
METHODS
This two-arm randomized controlled trial compared a progressive combined-aerobic and resistance-exercise intervention with usual care on baseline to 4-month changes in metabolic syndrome, body composition, and circulating biomarkers. The protocol and informed consent were approved by the institutional review board (HS-12-00141) and registered with ClinicalTrials.gov. Detailed methods have been published. 10 End points were assessed at baseline, postintervention (month 4), and at 3-month follow-up (exercise group only).
Participants, Recruitment, and Random Assignment
Eligible participants were , 6 months post-treatment for stage 0 to 3 breast cancer and were nonsmokers, sedentary (, 60 minutes of structured exercise per week), with body mass index (BMI) $ 25.0 kg/m 2 (or body fat . 30%) and waist circumference . 88 cm. Women were eligible regardless of baseline metabolic syndrome status and were prescreened on the basis of waist circumference given its strong association with insulin resistance. 11, 12 Recruitment occurred between August 1, 2012, and December 31, 2016, from the University of Southern California Norris Comprehensive Cancer Center and Los Angeles County Hospital. Participants were stratified by menopausal status and randomly assigned (block size = 10 patients) to exercise or usual care after baseline testing using concealed randomization lists.
Outcome Measures
Primary outcome was metabolic syndrome z-score that was calculated from modified z-scores of the following variables [13] [14] [15] [16] : waist circumference; systolic blood pressure; diastolic blood pressure (DBP); HDL cholesterol (HDL-C); triglycerides (TGs); and glucose using individual participant data, US National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria, and standard deviations (SDs; denominator of each factor in the formulas) using baseline data of the entire study cohort (N = 100) 13, 16 : ½ð50-HDLÞ=5:5 þ ½ðTG-15Þ=25:5 þ ½ðGlucose-100Þ=15:9 þ ½ðwaist circumference-88Þ=8:8 þ ½ðSBP-130Þ=11:4 þ ½ðDBP-85Þ=10:8
Metabolic syndrome criteria. On the basis of the ATP III definition, 17 metabolic syndrome constituted three or more of the following risk factors: waist circumference $ 88 cm, SBP $ 130 mm Hg or Hg DBP $ 85 mm or taking blood pressure medication, fasting levels of HDL-C , 50 mg/dL, TGs $ 150 mg/dL, and glucose $ 100 mg/dL or taking diabetes medication. The ATP III score of each participant was calculated by summing ATP III criteria met at each timepoint.
Serum biomarkers. Fasting ($ 12 hours) blood (~30 cc) was obtained from the antecubital vein by trained phlebotomists. Serum was stored at 280°celsius until batch analysis at study completion. Glucose, HDL-C, LDL cholesterol, total cholesterol, TGs, and glycosylated hemoglobin (HbA1c) were measured on a Vitros 4600 Analyzer (Ortho Clinical Diagnostics, Rochester, NY). High-sensitivity C-reactive protein was measured by immunoturbidmetric assay. Enzyme-linked immunosorbent assays were used to measure insulin, IL-6, IL-8, TNF-a, leptin, and adiponectin. Homeostasis model assessment (HOMA-IR) was used to estimate insulin resistance using the validated equation: Fasting Plasma Insulin 3 Fasting Plasma Glucose (mmol/L)/22.5. 18 Estradiol and testosterone were determined by liquid chromatographymass spectrometry. Sex hormone binding globulin was measured by doubleantibody radioimmunoassay (Roche Cobas: SHBG:03052001; Indianapolis, IN). Duplicate testing was performed with coefficients of variation for all samples , 10%.
Anthropometrics/dual-energy X-ray absorptiometry. Weight was measured to the nearest 0.1 kg on an electronic scale with the patient wearing a hospital gown and no shoes. Height was measured to the nearest 0.5 cm with a fixed stadiometer. Waist circumference was measured at the midpoint between the lower margin of the last palpable rib and the iliac crest. Hip circumference was measured around the widest portion of the buttocks. Whole-body dual-energy X-ray absorptiometry scans were performed to assess percent body fat, fat mass, appendicular skeletal mass, and lean mass (Lunar GE iDXA; Fairfield, CT). Sarcopenic obesity was defined as appendicular skeletal mass index , 5.45 kg/m 2 and BMI $ 30.0 kg/m 2 .
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Blood pressure. After 5 minutes of quiet sitting, blood pressure was measured by using the arm contralateral to the affected breast with an automated sphygmomanometer (Welch Allyn, Skaneateles Falls, NY).
Covariate Measures
Physical activity/dietary assessments. Physical activity history was assessed at baseline by using an interviewer-administered, validated questionnaire. 20 Three-day dietary records-2 weekdays and 1 weekend daywere completed at baseline, postintervention, and 3-month follow-up (exercise group only) within 1 week of each assessment and were analyzed using Nutritionist Pro (Axxya Systems, Woodinville, WA). Participants were asked to maintain dietary behaviors throughout the trial.
Medical history. Participants completed the Charlson comorbidity questionnaire. 21 Cancer-related information-disease stage, hormone receptor status, histologic grade, endocrine therapy, type and duration of chemotherapy, duration of radiation therapy, and surgery-was abstracted from medical records.
Physical Fitness Measures
A single-stage submaximal treadmill test was used to estimate maximal oxygen uptake. 22 Maximal voluntary strength (one-repetition maximum [1-RM]) was assessed for the chest press, latissimus pulldown, knee extension, and knee flexion using the 10-repetition maximum method (Tuff Stuff, Pomona, CA). 23 Results were used to quantify fitness and to prescribe exercise intensity for the intervention.
Exercise Intervention
The exercise program aligned with American College of Sports Medicine/American Cancer Society (ACSM/ACS) exercise guidelines for survivors of cancer-150 minutes of aerobic exercise and 2 to 3 days of resistance exercise training per week. 24, 25 Participants received three supervised one-on-one exercise sessions per week. Days 1 and 3 endorsed resistance and aerobic exercise of approximately 80 minutes, and day 2 included approximately 50 minutes of aerobic exercise. All sessions were led by a certified ACSM/ACS cancer exercise trainer. Participants wore a Polar heart monitor (Polar, Lake Success, NY) during each exercise session. The trainer documented attendance and minutes of exercise per session. Reasons for missing sessions were documented, with make-up sessions allowable up to 18 weeks. Details of the exercise intervention are provided in the Appendix (online only).
Usual Care Group
Participants who were randomly assigned to usual care were asked to log and maintain their current level of physical activity throughout the 16-week study period 26 and to wear an accelerometer daily during this period. At the completion of the 16-week study period, participants were offered the identical exercise intervention.
Statistical Analyses
At the time of project initiation, metabolic syndrome as a collective entity had not been investigated in survivors of breast cancer; thus, sample size was calculated by using changes in insulin 27 with a 16-week exercise intervention among survivors of breast cancer. Enrollment of 100 women provided 80% statistical power (a = .05) to detect a 2.6-mU/mL (SD = 4.0 mU/mL) difference in mean insulin levels, assuming 20% dropout using a two-group t test.
Within-group differences in mean changes for individual outcomes measured at 4 months and at 3-month follow-up (exercise group only) were evaluated by using general linear models repeated-measures analyses of variance. Between-group differences in mean changes for individual outcomes measured at 4 months were evaluated by using mixedmodel repeated-measures analysis. A priori covariates, including the type of treatment (chemotherapy, radiation, or both), surgery type, medication use (eg, antihypertensives and hyperglycemia medications), BMI, total kilocalorie intake, diet quality, and macronutrient distribution, were explored in models as a result of their possible associations with outcomes, but none modified results. Post hoc analyses included stratification by menopausal status at time of diagnosis. 28 Analyses were jco.org performed by using SAS (SAS/STAT User's Guide, Version 9.4; SAS Institute, Cary, NC). Figure 1 depicts the study schema. Baseline characteristics were similar across the two groups ( Table 1) . Attendance of 96%-average, 46 of 48 sessions-and adherence of 95% with aerobic and resistance exercises were observed in the exercise group. No adverse events were reported. Self-reports and accelerometry data suggested that the usual care group did not alter their physical activity levels over the study period. Results of our main outcomes did not vary by menopausal status (data not shown).
RESULTS

Changes in Metabolic Syndrome
At baseline, 77% of participants had metabolic syndrome (Table 2) . Postintervention, 15% of the exercise group and 80% of the usual care group had metabolic syndrome (x 2 = 10.7; P = .004). Table 3 lists the baseline, postintervention, and 3-month follow-up (exercise only) changes in metabolic syndrome variables by study group. The exercise group experienced significant improvements in all metabolic syndrome variables, including metabolic syndrome z-scores and ATP III scores compared with baseline (P , .01) and the usual care group (P , .001). At followup, all metabolic syndrome variables remained significantly improved in the exercise group compared with baseline (P , .001).
Changes in Sarcopenic Obesity and Body Composition
At baseline, 95% of our study population presented with sarcopenic obesity (data not shown). Postintervention, biomarkers of sarcopenic obesity, appendicular skeletal muscle index, and BMI were significantly reduced in the exercise group compared with baseline (P #.01) and the usual care group (P , .001; Table 4 ). The exercise group experienced significant decreases in body weight and all indicators of adiposity compared with baseline (P # .01) and the usual care group (P , .001). Lean mass increased significantly in the exercise group compared with baseline (P # .01) and the usual care group (P , .001). At follow-up, all body composition variables remained significantly improved in the exercise group compared with baseline (P , .001). Table 5 lists baseline, postintervention, and 3-month follow-up changes in circulating biomarker variables by group. The exercise group experienced significant reductions in all biomarkers, including those that are related to insulin resistance, proinflammatory markers, and estradiol, compared with baseline (P , .01) and the usual care group (P , .001), whereas insulin, HOMA-IR, leptin, and IL-8 were significantly increased in the usual care group (P , .01). At follow-up, all biomarkers, with the exception of free testosterone, remained significantly improved in the exercise group compared with baseline (P , .01).
Changes in Circulating Biomarkers
DISCUSSION
A supervised 16-week aerobic and resistance exercise intervention led to significant improvements in metabolic syndrome, sarcopenic obesity, and circulating biomarkers that were maintained at 3-month follow-up among ethnically diverse, sedentary, and overweight or obese survivors of breast cancer. This is the first study, to our knowledge, to significantly improve all components of metabolic syndrome with a structured exercise intervention in survivors of breast cancer. This work has the potential to change practice through the promotion of the ACSM/ACS exercise guidelines for survivors of cancer. Our work demonstrates the impact of these guidelines on cardiometabolic risk factors in a diverse population and may identify predictive biomarkers for additional study. As our intervention targeted women who had recently completed treatment, our results support the implementation of a structured exercise intervention early in the survivorship continuum. The prevalence of metabolic syndrome in this sample (77%) exceeds that of previous studies that reported a prevalence of 55.4%
13 and 59.2% 29 ; however, our results were similar to our previous observational study that reported 72.5% prevalence after 3 to 4 months of chemotherapy. 30 It is possible that this higher prevalence is a result of the large proportion of Hispanic white women (55%), who have a greater prevalence of metabolic syndrome compared with non-Hispanic whites, 31 as well as inclusion criteria that targeted sedentary and overweight or obese survivors of breast cancer. The necessity to establish the prevalence of metabolic syndrome in a larger cohort of survivors of breast cancer to plan for future personalized interventions is apparent.
The magnitude of benefit observed in the current study is impressive and parallels the findings of a pilot study by Nuri et al, 32 who found that a 15-week supervised, combined moderate-intensity exercise intervention significantly improved metabolic syndrome variables, with the exception of waist circumference, among 29 sedentary, overweight, postmenopausal survivors of breast cancerchanges that occurred in the presence of an approximate 1-kg decrease in body weight. In contrast, Thomas et al 13 and Guinan et al 33 †P value for repeated-measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up. ‡P value for mixed-model analysis comparing changes between the exercise and usual care group from baseline to postintervention.
jco.org
did not find significant improvements in metabolic syndrome after aerobic exercise in survivors of breast cancer, possibly because of lower adherence 13 and the inclusion of an active study population. 33 Our large, exercise-induced effects on metabolic syndrome also may be a result of the high rate of metabolic syndrome, high adherence, a supervised environment, and the inclusion of resistance exercise. Our adherence rate of 96% exceeds the 70% to 80% noted in other trials [34] [35] [36] and could be attributed to flexible session timing (5 AM to 8 PM, 7 days per week), one-on-one supervision, and the provision of parking permits or bus passes to overcome transportation barriers. In addition, we conducted the intervention in a controlled clinical setting under direct supervision to ensure exercise safety and dose intensity needed to offset metabolic dysregulation. 38 Resistance exercise was included in our intervention to elicit an impact on lean mass and glucose metabolism. Aerobic exercise has traditionally been viewed as the main mode of exercise that is effective at reducing waist circumference, fasting glucose, HDL-C, and TGs 13,33,39 ; however, aerobic exercise combined with resistance exercise alleviates metabolic syndrome and promotes functional improvements in muscular strength after the treatment of breast cancer.
7-9 Resistance exercise induces changes in insulin sensitivity by preserving and/or increasing lean body mass, increasing glucose storage, facilitating glucose clearance from circulation, and reducing the amount of insulin that is required to maintain normal glucose tolerance in obese adults. 40 Resistance exercise combined with aerobic exercise decreases metabolic syndrome in dyslipidemic men and women 7,15 and obese postmenopausal women, 41 similar to our study. Thus, combining resistance and aerobic exercise may improve metabolic health-related outcomes more than aerobic exercise alone, although no randomized controlled trials have directly addressed this question in survivors of breast cancer.
Sarcopenic obesity is an independent predictor of cancer survival. 42 In postmenopausal women, sarcopenic obesity is associated with elevated proinflammatory mediators-that is, C-reactive protein, TNF-a, and IL-6 43 -which is consistent with the high prevalence of sarcopenic obesity and heightened proinflammatory state at baseline that was observed in our study population. This is the first study, to our knowledge, to report the prevalence of sarcopenic obesity in survivors of breast cancer (95%), which is higher than that previously reported in postmenopausal women without a history of cancer (25%) 44 ; however, we recognize that our screening criterion-for example, waist circumference . 88 cm-predisposed our sample to sarcopenic obesity and metabolic syndrome. As no other previous investigations have examined combined exercise-induced changes in sarcopenic obesity in survivors of breast cancer, a direct comparison of past studies is lacking. Of relevance, Adams et al 45 reported a significant improvement in sarcopenia after a resistance exercise intervention for survivors of breast cancer who underwent chemotherapy, and Schmitz et al 46 found attenuated appendicular skeletal muscle mass in a 12-month weight lifting intervention among survivors of breast cancer. These results are in agreement with our study and support the potential of resistance exercise to elicit positive changes in lean mass in this high-risk population. Abbreviations: BMI, body mass index; SD, standard deviation. *P value for repeated-measures ANOVA comparing changes in the exercise group from baseline to postintervention, and in the usual care group from baseline to postintervention. †P value for repeated-measures ANOVA comparing changes in the exercise group from baseline to 3-month follow-up. ‡P value for mixed-model analysis comparing changes between the exercise and usual care group from baseline to postintervention.
The 4-kg weight loss observed in this study parallels the approximate 5-kg loss reported in another study that also included diet counseling among survivors of breast cancer. 47 As dietary intake, diet quality, and macronutrient composition remained unchanged, the significant weight loss that resulted from our exercise-alone intervention is possibly a result of the increased energy expenditure from a controlled exercise stimulus within this sedentary population. We estimated that each combined exercise session resulted in an approximate 500-kcal energy expenditure; therefore, it is possible that this induced a large enough caloric deficit over the entire study period to result in weight loss.
The intervention also resulted in reductions in insulin resistance and proinflammatory and hormonal biomarkers hypothesized to mediate the relationship between obesity and breast cancer. 48, 49 These effects are consistent with the extant literature on exercise interventions in survivors of breast cancer, which has been recently summarized by two systematic reviews with meta-analysis.
50,51
These meta-analyses found that exercise decreased the serum concentrations of IL-6, TNF-a, and IL-2.
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Hyperinsulinemia/insulin resistance is associated with increased cancer recurrence and mortality, 52,53 presumably as a result of the promotion of the survival and growth of residual cancer cells; thus, the decreases in circulating insulin and HOMA-IR with exercise that were observed in the current study represent an additional mechanism that might translate into survival benefits. Whereas a variety of exercise approaches have been shown to reduce insulin Abbreviations: HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high sensitivity C-reactive protein; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth factor binding protein-3; SD, standard deviation; SHBG, sex hormone binding globulin; TNF-a, tumor necrosis factor-a.levels in survivors of cancer, 51 it is unclear which exercise methodology will provide optimal results. Future studies that evaluate exercise type, setting (clinic, home based, with or without supervision), frequency, intensity, time, and intervention period on insulin sensitivity are needed to best advise clinical practice and patient care.
Overall, our work provides support for the adoption of the ACSM/ACS exercise guidelines for survivors of breast cancer. This work also underscores the need for future fully powered investigations that examine the effects of exercise and other energy balance-derived interventions-that is, diet and diet plus exerciseon physiologic and cancer outcomes in survivors of breast cancer. Ongoing interventions, such as the Breast Cancer Weight Loss study, 54 aim to address the impact of weight loss on cancer recurrence; however, the question remains as to whether an exercise intervention alone will benefit cardiometabolic and cancer outcomes.
On the basis of our findings and past studies, future work requires designing investigations to examine the effects of precisionderived-that is, varying modes and intensity for each patientexercise interventions on metabolic syndrome; designing and implementing home-or community-based exercise interventions that are more easily disseminated; and assessing the potential effect that the attenuation of metabolic syndrome has on mortality rates-our ongoing follow-up analysis will provide preliminary data to address this point. We are currently testing a novel exercise intervention that is designed to elicit greater benefits on cardiometabolic factors in survivors of breast cancer (ClinicalTrials.gov identifier: NCT03284346) that may progress the current exercise paradigm for survivors of cancer.
Strengths of our study include a focus on high-risk survivors of breast cancer with high rates of metabolic syndrome, inactivity, and obesity; the ethnically diverse sample; the comprehensive assessment of metabolic syndrome components and markers; use of a continuous metabolic syndrome score that replicated that used in cancer 13 and noncancer populations 16 ; the randomized controlled trial design; the high adherence rate; and the modest lossto-follow-up rate. Limitations include possible recruitment bias, a lack of intervention reproducibility with high adherence outside of a supervised setting (eg, home-based or virtually coached exercise interventions), lack of an attention control group, and limited frequency of dietary recall information.
In summary, our findings support supervised aerobic and resistance exercise as an effective strategy to attenuate metabolic syndrome, body composition, and serum biomarkers in survivors of breast cancer. Our findings support the incorporation of supervised clinical exercise programs into breast cancer treatment and survivorship care plans.
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